Check patentability & draft patents in minutes with Patsnap Eureka AI!

Novel benzamide derivatives and process for production thereof

A technology of benzamide and derivatives, applied in the new field of benzamide, can solve the problems of low efficiency, not an industrial manufacturing method, difficulty in estimating and controlling reaction conditions, etc.

Inactive Publication Date: 2006-03-29
ASTELLAS PHARMA INC
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] However, according to the description of this patent publication, the target compound N-{2-[3-(6,7-dimethyl The total yield of oxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-3,4-methylenedioxybenzamide hydrochloride was about It is 16% (referring to the reference example 2, reference example 3 and embodiment 9 of said patent publication) and its efficiency is very low
In addition, purification by column chromatography is required, which is not the preferred method for industrial manufacturing
In addition, during benzoylation of primary amines (which is the last step in the production process X), diacyl compounds may be produced and it is estimated that controlling the reaction conditions is very difficult
In addition, amino derivatives protected as phthalimides are used, therefore, deprotection will generate waste, which is also a problem in industrial production processes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel benzamide derivatives and process for production thereof
  • Novel benzamide derivatives and process for production thereof
  • Novel benzamide derivatives and process for production thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0120] To 120.0 g of the compound of Reference Example 11 were added 1,200 ml of toluene and 137.07 g of ethyl (R)-piperidine-3-carboxylate. (R)-Piperidine-3-carboxylic acid ethyl ester was washed with 600 ml of toluene. Thereafter, 145.1 g of p-toluenesulfonic acid monohydrate was added thereto, followed by washing with 600 ml of toluene. The reaction mixture was heated and the solvent was distilled under normal pressure to evaporate 600 ml therefrom. Afterwards, the reaction mixture was stirred at reflux for 27 hours. After the mixed solution was cooled, 960 ml of EtOAc and 960 ml of 4% (w / v) NaHCO were added 3 aqueous solution. The reaction mixture was allowed to stand at about 35°C to separate the layers. The obtained organic layer was washed with 960 ml of 4% (w / v) NaHCO 3 Wash twice with aqueous solution. The organic layer was concentrated under vacuum to give ethyl (R)-1-{2-[(4-fluorobenzoyl)amino]ethyl}piperidine-3-carboxylate with a purity of 82.8%.

[0121] NM...

Embodiment 2

[0124] To 230 g of the compound of Example 1 was added 690 ml of EtOH, and then 345 ml of water was added thereto. After cooling, an aqueous NaOH solution (42.8 g of NaOH / 480 ml of water) was added, followed by stirring at 25° C. or lower for 2 hours. After cooling, concentrated hydrochloric acid was added to the reaction mixture to adjust the pH to 3.0. The solution was concentrated under vacuum, 1,000 mL of toluene was added to the residue, and the mixture was concentrated under vacuum to give (R)-1-{2-[(4-fluorobenzoyl)amino]ethyl}piperidine -3-Carboxylic acid with a purity of 86.3%.

[0125] NMR (90°C): δ1.46-1.60 (1H, m), 1.79-2.05 (3H, m), 2.75-3.60 (7H, m), 3.68 (2H, q), 7.20-7.27 (2H, m) , 7.95-8.03 (2H, m), 8.74 (1H, brs).

[0126] FAB-MS m / z: 295 (M + +1).

Embodiment 3

[0128] 810 ml of DMF and 120.8 g of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline monohydrochloride were added to 206.4 g of the compound of Example 2, followed by stirring and cooling. After that, 53.22 g of triethylamine was added at 12° C. or lower, and then 217 ml of DMF was added. Then 21.32 g of HOBt was added at 5°C or lower, followed by 121.0 g of WSC.HCl at 5°C or lower. The reaction mixture was stirred at 0-4°C for 15.5 hours. 340 mL of water, 2,000 mL of EtOAc and 550 mL of 8% (w / v) NaOH aqueous solution were added to the reaction mixture, and then the layers were separated. EtOAc (1,000 mL) was added to the aqueous layer and the layers were separated. After that, the organic layers were mixed and washed twice with 700 mL 8% (w / v) NaOH aqueous solution and 300 mL water. After the organic layer was washed with 900 ml of water, it was concentrated under vacuum to give (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetra Hydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A novel process for the production of isoquinoline derivatives having inhibitory activity against current If; novel benzamide derivatives or salts thereof which are to be used in the process; and a process for the production of the benzamide derivatives or the salts.

Description

field of invention [0001] The present invention relates to novel benzamides, which are manufactured as I f Useful intermediates for isoquinoline derivatives of current suppressors, and to processes for the manufacture of the same and for the manufacture of isoquinoline derivatives from said novel benzamide derivatives. Background of the invention [0002] It is known that the isoquinoline derivatives represented by the following formula (A) pair I f The current has an inhibitory effect, and shows a strong and specific activity of selectively slowing down the heartbeat and reducing myocardial oxygen consumption, so it can be used as a therapeutic agent for ischemic heart disease (such as angina pectoris and myocardial infarction), congestive heart failure, Preventive and / or therapeutic agents for circulatory diseases such as cardiac arrhythmia. (Patent Document 1). [0003] [0004] (Refer to the corresponding patent publication for the meaning of the symbols in this fo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D211/60C07D401/06
CPCC07D211/60C07D401/06A61P9/04A61P9/06A61P9/10A61K31/166
Inventor 吉田信也渡边俊博丸茂清隆掛札昭夫
Owner ASTELLAS PHARMA INC
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More